Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method of treating lung cancer by vaccination with MUC-1 lipopeptide

A lipopeptide, lung cancer technology, applied in the field of non-small cell lung cancer

Inactive Publication Date: 2016-01-27
MERCK PATENT GMBH
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although CPA lacks any appreciable activity in NSCLC, and the doses used in this setting are lower than those used in cytotoxic chemotherapy, it is currently believed that the observed antitumor effects of L-BLP25 therapy can be attributed to the effects of CPA. Immunomodulatory effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of treating lung cancer by vaccination with MUC-1 lipopeptide
  • Method of treating lung cancer by vaccination with MUC-1 lipopeptide
  • Method of treating lung cancer by vaccination with MUC-1 lipopeptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0031] The mucin / muc-1 peptide according to the invention is a mature human glycoprotein directed against the muc-1 antigen comprising the following 20 amino acid muc-1 core repeat peptide unit:

[0032] STAPPAHGVTSAPDTRPAPGTAPPAHGVTSAPDTRPAPGSAPPAHGVTSAPDTRPAPGSTPPAHGVTSAPDTRPAPGSTAPAHGVTSAPDTRPAPGSTAPAHGVTSAPDTRPAPGSTAPPHGVTSAPDTRPAPGSTAPPAGVTSAPDTRPAPGSTAPPAHVTSAPDTRPAPGSTAPPAHGTSAPDTRPAPGSTAPPAHGVSAPDTRPAPGSTAPPAHGVTAPDTRPAPGSTAPPAHGVTSPDTRPAPGSTAPPAHGVTSADTRPAPGSTAPPAHGVTSAPTRPAPGSTAPPAHGVTSAPDRPAPGSTAPPAHGVTSAPDTPAPGSTAPPAHGVTSAPDTRAPGSTAPPAHGVTSAPDTRPPGSTAPPAHGVTSAPDTRPAGSTAPPAHGVTSAPDTRPAP

[0033] Including (i) all biologically active isoforms, variants, mutants and truncated forms thereof, including glycosylated, aglycosylated, partially glycosylated forms, and including glycosylated and and / or in the form of amino acid residue patterns; (ii) any biologically active recombinant or synthetic 20mer peptide consisting of any of the above core repeat peptide units, incl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention is directed to the treatment of lung cancer, preferably non-small cell lung cancer (NSCLC) by means of a combination therapy comprising concurrent chemo-radiotherapy followed by vaccination with a muc-1 lipopetide. The therapy elicits prolonged survival rates compared to a respective therapy including sequential chemo-radiotherapy.

Description

Area of invention [0001] The present invention involves combined therapy including synchronous chemical radiation therapy and then inoculation of MUC-1 fat peptide to treat lung cancer, preferred, non-small cell lung cancer (NSCLC).Compared with the corresponding therapy for sequential chemical radiation therapy, the therapy causes an extended survival rate. Invention background [0002] Lung cancer is the main cause of human cancer death, with a total survival rate of about 10-15%.The needs of limited efficacy and toxicity related to non -small cell lung cancer (NSCLC) chemotherapy for more safer and more effective treatment options.With the identification of tumor -related antibodies and antigen (TAA) in patients with lung cancer, immunotherapy has become an attractive choice. [0003] Vision 1 (MUC1) is such a TAA, which is an excessively expressed glucose protein in NSCLC.The MUC1 antigen surface positions combined with HLAI -like molecules have been identified, and the blood...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/17A61P35/00A61K33/243
CPCA61K38/1735A61K9/127A61K31/675A61K45/06A61K31/337A61K31/475A61K31/519A61K31/555A61K31/7048A61K31/7068A61K2039/55555A61K47/542A61P35/00A61P43/00A61K39/00117A61K33/243A61K2300/00A61K33/24A61K39/0011A61K39/0012A61K39/39A61K2039/55572A61N5/10
Inventor A.施勒德C.黑尔维希A-H.卢斯A.许勒尔M.法尔克C.布茨F.A.谢泼德
Owner MERCK PATENT GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com